TY - JOUR
T1 - An Antihuman Epidermal Growth Factor Receptor 2 Monoclonal Antibody (H2Mab-19) Exerts Antitumor Activity in Glioblastoma Xenograft Models
AU - Kato, Yukinari
AU - Ohishi, Tomokazu
AU - Takei, Junko
AU - Nakamura, Takuro
AU - Kawada, Manabu
AU - Kaneko, Mika K.
N1 - Funding Information:
This research was supported, in part, by Japan Agency for Medical Research and Development (AMED) under Grant Numbers JP20am0401013 (Y.K.), JP20am0101078 (Y.K.), and JP20ae0101028 (Y.K.), and by Japan Society for the Promotion of Science ( JSPS) KAKENHI under Grant Numbers 17K07299 (M.K.K.) and 19K07705 (Y.K.).
Publisher Copyright:
© Copyright 2020, Mary Ann Liebert, Inc., publishers 2020.
PY - 2020/8/1
Y1 - 2020/8/1
N2 - Overexpression of human epidermal growth factor receptor 2 (HER2) has been reported in glioblastoma as well as breast, gastric, lung, colorectal, and pancreatic cancers. Its expression is associated with poor clinical outcomes. Anti-HER2 antibodies have provided significant survival benefits to patients with HER2-overexpressing breast and gastric cancers. We recently developed an anti-HER2 monoclonal antibody (mAb), H2Mab-19 (IgG2b, kappa), by immunizing mice with the extracellular domain of HER2, which is expressed in LN229 glioblastoma cells. In this study, we investigated the antitumor activity of H2Mab-19 in an LN229 glioblastoma xenograft model. H2Mab-19 showed high binding affinity (KD: 1.1 × 10-8 M) against LN229 cells. Furthermore, H2Mab-19 significantly reduced tumor development in an LN229 xenograft. These results suggest that treatment with H2Mab-19 may be a useful therapy for patients with HER2-expressing glioblastomas.
AB - Overexpression of human epidermal growth factor receptor 2 (HER2) has been reported in glioblastoma as well as breast, gastric, lung, colorectal, and pancreatic cancers. Its expression is associated with poor clinical outcomes. Anti-HER2 antibodies have provided significant survival benefits to patients with HER2-overexpressing breast and gastric cancers. We recently developed an anti-HER2 monoclonal antibody (mAb), H2Mab-19 (IgG2b, kappa), by immunizing mice with the extracellular domain of HER2, which is expressed in LN229 glioblastoma cells. In this study, we investigated the antitumor activity of H2Mab-19 in an LN229 glioblastoma xenograft model. H2Mab-19 showed high binding affinity (KD: 1.1 × 10-8 M) against LN229 cells. Furthermore, H2Mab-19 significantly reduced tumor development in an LN229 xenograft. These results suggest that treatment with H2Mab-19 may be a useful therapy for patients with HER2-expressing glioblastomas.
KW - HER2
KW - antitumor activity
KW - glioblastoma
KW - monoclonal antibody
UR - http://www.scopus.com/inward/record.url?scp=85089801425&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85089801425&partnerID=8YFLogxK
U2 - 10.1089/mab.2020.0013
DO - 10.1089/mab.2020.0013
M3 - Article
C2 - 32644843
AN - SCOPUS:85089801425
SN - 2167-9436
VL - 39
SP - 135
EP - 139
JO - Monoclonal Antibodies in Immunodiagnosis and Immunotherapy
JF - Monoclonal Antibodies in Immunodiagnosis and Immunotherapy
IS - 4
ER -
